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Abstract
Catecholaminergic polymorphic ventricular tachycardia is a familial cardiac arrhythmia that is 
related to RYR2 or CASQ2 gene mutation. It occurs in patients with structurally normal heart 
and causes exercise-emotion triggered syncope and sudden cardiac death. We present a 13 
year-old girl with recurrent episodes of exercise-related syncope and prior history of sudden 
death in a first degree relative.                                                                          
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A 13-year-old girl with no cardiovascular history presented for evaluation of recurrent 
episodes of exercise-related syncope and prior history of sudden death in a first degree 
relative. The 12- lead electrocardiogram (ECG) at rest was normal and an echocardiogram 
confirmed a structurally normal heart. A 24-hour Holter monitoring (Figure 1, left panel) 
during   physical   activity   showed   the   classic   electrocardiographic   manifestation   of 
catecholaminergic polymorphic ventricular tachycardia (CPVT): bidirectional ventricular 
tachycardia (BVT), two alternating QRS complexes morphologies with different polarity (X 
and Y, Figure 1 right panel) with an XY interval of 240 ms and YX interval of 280 ms. It 
may be necessary to conduct a 12-lead ECG to confirm if those polarities represented right 
bundle branch block and left bundle branch block respectively. The BVT presented regular X-
X and Y-Y intervals both at 520 ms. According to the classification originally proposed by 
Scherf and Kisch, the BVT presented here is a Type II BVT, defined by a regular and fixed 
alternation of short and long intervals.[1,2]
The patient was treated with propanolol 120 mg/day. During a control exercise stress test the 
patient presented again with CPVT symptomatic by syncope. An implantable automatic 
cardioverter defibrillator was implanted (PRIZM DR, Guidant, MN, USA). Genetic screening 
was not performed at the time of writing this report.
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Figure 1. Left Panel: 24-Hour Holter monitoring. During physical activity, BVT is precipitated by ventricular 
bigeminy degenerating into polymorphic ventricular tachycardia and ventricular fibrillation. Right Panel: 
amplification of a segment of the 24-hour Holter monitoring depicting alternating QRS complex morphologies 
with different  polarities, characteristic features  of BVT.                                                                 
This tachycardia suddenly degenerated into self-limiting polymorphic ventricular tachycardia 
and ventricular fibrillation (Figure 1, left panel), and normal sinus rhythm resumed upon 
spontaneous cessation of ventricular fibrillation. The resting 12-lead ECG was normal after 
the event. (Figure 2)
During a ten year follow-up, the patient presented with three episodes of polymorphic 
ventricular tachycardia requiring ICD shocks. Propranolol dose was increased (160 mg/day) 
and the patient remained asymptomatic for the last two years.                                   
                                                                                                                         
CPVT is a rare but highly malignant (syncope or sudden cardiac death) genetic disease related 
to the mutation of cardiac ryanodine receptor gene (RYR2) or calsequestrin 2 gene (CASQ2), 
leading to an increase in intracellular Ca++ concentration, resulting in arrhythmia due to a 
cascade of delayed after depolarization and triggered activity [3-6], and the four distinguishing 
features of CPVT have subsequently been described by Coumel et al [7]: 1) normal resting 
electrocardiogram; 2) exercise- or emotion-induced severe ventricular tachycardia; 3) a typical 
pattern of bidirectional ventricular tachycardia; and 4) a structurally normal heart.       
BVT has been described in a variety of clinical settings including digitalis toxicity, herbal 
aconite  poisoning, hypokalemic  periodic  paralysis, myocarditis, coronary  artery  disease, 
metastatic cardiac tumors, non-ischemic dilated cardiomyopathy, Anderson-Tawil syndrome, 
and at the same time, has been recognized as a hallmark of CPVT.[8]  It is usually triggered by 
exercise or emotional stress. It can be precipitated by premature ventricular contractions or 
ventricular   bigeminy.   As   in   this   case,   it   can   degenerate   into   polymorphic   ventricular 
tachycardia and ventricular fibrillation.
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Figure 2. Normal resting 12-lead electrocardiogram
The treatment is directed to suppress adrenergic activity, therefore beta-blockers are the most 
important drug in the treatment of CPVT. Beta-blockers are effective for the acute phase and 
maintenance treatment. However, if symptoms recur, ICD should be considered. Flecainide is 
also part of the armamentarium to treat this infrequent disease [9].                        
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 12 (2): 65-68 (2012)Femenia F et al, “Bidirectional Ventricular Tachycardia: A Hallmark of CPVT”                68
References
1. Siegal D, Quinlan C, Parfrey B, Simpson CS, Redfearn DP, Baranchuk A. Type II 
bidirectional ventricular tachycardia as a mechanism of termination of sustained ventricular 
tachycardia. J Cardiovasc Electrophysiol 2009; 20: 345-6.                                     
2. Schamroth L. Ventricular Tachycardia and Ventricular Flutter. In: The Disorders of Cardiac 
Rhythm: Blackwell Science Ltd.; London, 1980; chapter 23, pp.107-115.                         
3. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M et al. Clinical and 
molecular   characterization   of   patients   with   catecholaminergic   polymorphic   ventricular 
tachycardia. Circulation 2002; 106: 69–74.                                                                             
4. Ylanen K, Poutanen T, Hiippala A, Swan H, Korppi M. Catecholaminergic  polymorphic 
ventricular tachycardia. Eur J Pediatr 2010; 169: 535–542.                                           
5. Femenia F, Perez Riera AR. Estratificacion del riesgo en las canalopatias congenitas. Revista 
Iberoamericana de Arritmología 2011; doi: 10.5031/v1i2.RIA10119.                                   
6. Baher AA, Uy M, Xie F, Garfinkel A, Qu Z, Weiss JN. Bidirectional ventricular tachycardia: 
ping pong in the His-Purkinje system. Heart Rhythm 2011; 8: 599-605.                    
7. Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholaminergic-induced severe 
ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. Br Heart 
J   1978;   40:   28-37.                                                                            
8. Sonmez O, Gul EE, Duman C, Duzenli MA, Tokac M, Cooper J. Type II bidirectional 
ventricular tachycardia in a patient with myocardial infarction. J Electrocardiol 2009, 42: 631-
632.
9. Biernacka EK, Hoffman P. Efficacy of flecainide in a patient with catecholaminergic 
polymorphic ventricular tachycardia. Europace 2011; 13: 129-30. 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 12 (2): 65-68 (2012)